Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01794039 · OUTCOME

Time to Progression

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide · Source last updated 2018-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Time from registration to the earliest date with documentation of disease progression, assessed up to 2 years

What was measured

The distribution of time to progression will be estimated using the method of Kaplan-Meier. The International Myeloma Working Group (IMWG) uniform response criteria (Rajkumar et al, 2011) will be used to assess response to therapy.

Analysis population: All patients that received Arm A or Arm B treatment.

Groups in this outcome

Arms A and B

4 arm A patients were transferred to Arm B for further treatment. Arm A patients, that went off study for any reason, were allowed to transfer to Arm B

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arms A and B9

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arms A and B10Not reported4.112.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.1
        upper Limit
        12.4
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
The distribution of time to progression will be estimated using the method of Kaplan-Meier. The International Myeloma Working Group (IMWG) uniform response criteria (Rajkumar et al, 2011) will be used to assess response to therapy.
dispersion Type
95% Confidence Interval
groups
  1. description
    4 arm A patients were transferred to Arm B for further treatment. Arm A patients, that went off study for any reason, were allowed to transfer to Arm B
    id
    OG000
    title
    Arms A and B
param Type
MEDIAN
population Description
All patients that received Arm A or Arm B treatment.
reporting Status
POSTED
time Frame
Time from registration to the earliest date with documentation of disease progression, assessed up to 2 years
title
Time to Progression
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice